CC化学因子调节肺高血压中的免疫反应
Qian Yan1, Shasha Liu2, Yang Sun1
1Hunan Engineering Technology Center of Standardization and Function of Chinese Herbal Decoction Pieces, College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Journal of advanced research
|November 5, 2023
概括
CC化学因子通过促进免疫细胞透和炎症来驱动肺高血压 (PH). 针对这些化学因子及其受体可能为PH提供治疗策略,尽管目前临床试验面临挑战.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部医学 肺部医学
- 分子生物学分子生物学
背景情况:
- 肺高血压 (PH) 涉及肺动脉重塑,右心力衰竭和死亡率,由炎症和免疫失调驱动.
- 化学物质,特别是CC化学物质,对于免疫细胞招募和PH病原体的炎症反应至关重要.
- 本综述综合了CC化基因在免疫恒温和PH内的炎症中的作用.
研究的目的:
- 检查CC化学因子对PH中的各种免疫细胞的免疫调节作用.
- 探索PH中的致病机制,包括热和BMPR2突变相互作用.
- 审查关于PH中的免疫细胞和CC化学因子的实验发现.
主要方法:
- 文献综述综合了现有关于PH中CC化学因子和免疫细胞的研究.
- 对病原机制的分析,包括细胞热致死和BMPR2信号的分析.
- 对免疫细胞参与PH的检查.
主要成果:
- CC化学因子在免疫细胞平衡和与PH相关的炎症反应中发挥着重要作用.
- 了解细胞热和BMPR2突变交叉对PH病理生理学至关重要.
- 实验数据强调了向免疫细胞和CC化学因子的影响.
结论:
- CC化学因子及其受体是减轻PH炎症的有希望的治疗点.
- 临床翻译面临障碍,但研究可能会推进新的PH疗法.
- 为了有效的PH管理,需要进一步开发针对CC化学因子的治疗剂.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
194
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
194
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
COPD: Pathogenesis and Clinical Features
302
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
302


